Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.K. (FTSE) Pharma Industry Analysis

UpdatedJun 05, 2026
DataAggregated Company Financials
Companies17
  • 7D-1.4%
  • 3M-7.0%
  • 1Y19.2%
  • YTD-0.6%

Over the last 7 days, the Pharma industry has dropped 1.4%, driven by AstraZeneca declining 1.3%. On the other hand Poolbeg Pharma is actually up 50%. In the past year, the industry has gained 19%. As for the next few years, earnings are expected to grow by 10% per annum.

Industry Valuation and Performance

Has the U.K. Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 05 Jun 2026UK£321.0bUK£92.0bUK£15.8b17.5x20.3x3.5x
Sun, 03 May 2026UK£321.8bUK£91.4bUK£15.7b18.4x20.5x3.5x
Tue, 31 Mar 2026UK£349.0bUK£91.4bUK£15.8b20.1x22.1x3.8x
Thu, 26 Feb 2026UK£364.4bUK£90.0bUK£15.4b22.5x23.7x4x
Sat, 24 Jan 2026UK£322.4bUK£88.9bUK£14.5b22.2x22.2x3.6x
Mon, 22 Dec 2025UK£323.8bUK£89.7bUK£14.6b21.9x22.1x3.6x
Wed, 19 Nov 2025UK£320.5bUK£90.5bUK£14.8b21.4x21.7x3.5x
Fri, 17 Oct 2025UK£297.4bUK£87.7bUK£11.7b20.2x25.4x3.4x
Sun, 14 Sep 2025UK£282.1bUK£87.3bUK£11.7b21.2x24.2x3.2x
Tue, 12 Aug 2025UK£265.3bUK£87.7bUK£11.7b21x22.6x3x
Thu, 10 Jul 2025UK£258.0bUK£86.1bUK£10.6b25.5x24.4x3x
Sat, 07 Jun 2025UK£271.9bUK£86.3bUK£10.6b27.2x25.6x3.1x
Mon, 05 May 2025UK£268.3bUK£87.4bUK£10.7b26.7x25x3.1x
Wed, 02 Apr 2025UK£278.5bUK£87.7bUK£9.7b32.2x28.7x3.2x
Fri, 28 Feb 2025UK£288.7bUK£88.8bUK£9.7b28.7x29.6x3.3x
Sun, 26 Jan 2025UK£234.4bUK£75.6bUK£7.8b32.9x30x3.1x
Tue, 24 Dec 2024UK£223.3bUK£75.5bUK£7.8b31.2x28.7x3x
Thu, 21 Nov 2024UK£215.0bUK£75.1bUK£7.7b30.1x27.8x2.9x
Sat, 19 Oct 2024UK£252.7bUK£72.3bUK£9.0b30.9x27.9x3.5x
Mon, 16 Sep 2024UK£259.0bUK£72.1bUK£9.0b37.7x28.7x3.6x
Wed, 14 Aug 2024UK£273.3bUK£72.9bUK£9.1b40x30.1x3.8x
Fri, 12 Jul 2024UK£256.4bUK£70.9bUK£9.5b30.3x27.1x3.6x
Sun, 09 Jun 2024UK£268.8bUK£71.5bUK£9.6b30.5x28.1x3.8x
Tue, 07 May 2024UK£265.3bUK£71.9bUK£9.6b33x27.6x3.7x
Thu, 04 Apr 2024UK£240.9bUK£70.7bUK£9.7b31.9x24.8x3.4x
Sat, 02 Mar 2024UK£233.2bUK£70.7bUK£9.7b30.8x23.9x3.3x
Mon, 29 Jan 2024UK£237.3bUK£68.9bUK£10.7b35.9x22.2x3.4x
Wed, 27 Dec 2023UK£232.3bUK£68.9bUK£10.7b34.8x21.8x3.4x
Fri, 24 Nov 2023UK£226.9bUK£69.4bUK£10.7b52.9x21.1x3.3x
Sun, 22 Oct 2023UK£234.8bUK£70.7bUK£10.4b53.5x22.7x3.3x
Tue, 19 Sep 2023UK£241.9bUK£70.0bUK£10.3b53.5x23.5x3.5x
Thu, 17 Aug 2023UK£238.5bUK£68.9bUK£10.1b53.5x23.5x3.5x
Sat, 15 Jul 2023UK£226.8bUK£66.6bUK£7.8b54.3x29.2x3.4x
Mon, 12 Jun 2023UK£250.7bUK£68.2bUK£7.9b55.1x31.6x3.7x
Price to Earnings Ratio

31.6x


Total Market Cap: UK£250.7bTotal Earnings: UK£7.9bTotal Revenue: UK£68.2bTotal Market Cap vs Earnings and Revenue0%0%0%
U.K. Pharma Industry Price to Earnings3Y Average 25.4x202420252026
Current Industry PE
  • Investors are pessimistic on the British Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 20.3x which is lower than its 3-year average PE of 25.4x.
  • The industry is trading close to its 3-year average PS ratio of 3.4x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 26% per year over the last three years.
  • Revenues for these companies have grown 11% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the U.K. Healthcare industry?

GB Market-0.63%
Healthcare-1.27%
Pharma-1.41%
Pharma-1.41%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
POLB Poolbeg PharmaUK£0.08450.0%
+UK£19.7m		140.0%PB6.9x
INC IncantheraUK£0.01949.0%
+UK£862.1k		-62.0%PS436.8x
IMM ImmuPharmaUK£0.0443.0%
+UK£811.1k		65.6%PB40.2x
NFX NuformixUK£0.00172.1%
+UK£91.3k		64.4%PB2.7x

Latest News

HIK
UK£14.60
Hikma Pharmaceuticals
7D
-1.2%
1Y
-30.6%
HLN
UK£3.30
Haleon
7D
-3.5%
1Y
-18.2%
GSK
UK£19.02
GSK
7D
-0.8%
1Y
25.8%
AZN
UK£135.54
AstraZeneca
7D
-1.3%
1Y
26.7%
Narrative Update • Jun 03

AZN: Recent Drug Approvals And Key Readouts Will Support Bullish Repricing

Analysts have lifted their AstraZeneca price targets by up to £1,000 per share, pointing to updated valuation work that reflects Baxfendy's FDA approval, recent price target revisions from several banks, and slight tweaks to fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Recent research around AstraZeneca clusters into two camps, with some analysts leaning more optimistic after Baxfendy's approval and a series of price target moves, while others highlight execution and regulatory questions that could affect how those targets are met.
IMM
UK£0.044
ImmuPharma
7D
3.0%
1Y
65.6%
HCM
UK£1.73
HUTCHMED (China)
7D
-4.2%
1Y
-23.0%
Narrative Update • May 28

HCM: Late-Stage Hematology And Oncology Pipeline Will Drive Future Re-Rating Potential

Analysts have kept their fair value estimate for HUTCHMED (China) steady at £3.46 per share, with only marginal tweaks to assumptions such as discount rate, revenue growth, profit margin and future P/E. Together, these factors support an unchanged price target narrative.
STX
UK£0.058
Shield Therapeutics
7D
-5.7%
1Y
125.2%
Narrative Update • May 21

STX: Pediatric And Asia Regulatory Milestones Will Drive Future Earnings Upside

Shield Therapeutics’ latest analyst price target has been set at £0.14, with analysts attributing this unchanged fair value to a slightly adjusted discount rate, modestly revised revenue growth and profit margin assumptions, and a recalibrated future P/E multiple. What's in the News MEDLEAP Pharma, a subsidiary of Vital KSK Holdings Inc., enrolled the first patient in a Phase II exploratory clinical trial in Japan evaluating ACCRUFeR (ferric maltol) for Pulmonary Arterial Hypertension.
POLB
UK£0.084
Poolbeg Pharma
7D
50.0%
1Y
140.0%
EAH
UK£0.93
ECO Animal Health Group
7D
-3.1%
1Y
48.8%
AGY
UK£0.089
Allergy Therapeutics
7D
-1.1%
1Y
20.3%
NFX
UK£0.0017
Nuformix
7D
2.1%
1Y
64.4%
INC
UK£0.019
Incanthera
7D
49.0%
1Y
-62.0%